Partial response to anakinra in life-threatening Henoch-Schönlein purpura: Case report

Pediatric Rheumatology

Volumn 9, Issue , 2011, Pages

  Boyer, Erynn M ^a   Turman, Martin ^a   O'Neil, Kathleen M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CREATININE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ANAPHYLACTOID PURPURA; ANKLE PAIN; ARTICLE; BRAIN VASCULITIS; CASE REPORT; CHILD; CREATININE BLOOD LEVEL; DYSPNEA; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; HYPOXEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LUNG HEMORRHAGE; LUNG LAVAGE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEINURIA; RASH; SCHOOL CHILD; SWELLING; VOMITING;

EID: 80051489634     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-9-21     Document Type: Article

References (43)

1. Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F. Clinical outcome in children with Henoch-Schönlein nephritis. Pediatric Nephrology 2007, 22(1):64-70. 10.1007/s00467-006-0278-0, 17024391.
2. Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet 2007, 369(9566):976-8. 10.1016/S0140-6736(07)60474-7, 17382810.
3. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine 1999, 78(6):395-409. 10.1097/00005792-199911000-00005, 10575422.
4. Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics 2010, 126(4):674-81. 10.1542/peds.2009-3348, 20855386.
5. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics 2007, 120(5):1079-87. 10.1542/peds.2007-0667, 17974746.
6. Shenoy M, Bradbury MG, Lewis MA, Webb NJ. Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatric Nephrology 2007, 22(10):1717-22. 10.1007/s00467-007-0557-4, 17647023.
7. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura. Journal of Pediatrics 2003, 143(5):658-61. 10.1067/S0022-3476(03)00502-X, 14615741.
8. Butani L, Morgenstern BZ. Long-term outcome in children after Henoch-Schönlein purpura nephritis. Clinical Pediatrics 2007, 46(6):505-11. 10.1177/0009922806298896, 17579102.
9. Saulsbury FT. Henoch-Schönlein purpura. Current Opinion in Rheumatology 2001, 13(1):35-40. 10.1097/00002281-200101000-00006, 11148713.
10. Soylemezoglu O, Ozkaya O, Ozen S, Bakkaloglu A, Dusunsel R, Peru H, et al. Henoch-Schönlein nephritis: a nationwide study. Nephron 2009, 112(3):c199-c204.
11. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis & Rheumatism 1990, 33(8):1114-21.
12. Tizard EJ. Henoch-Schönlein purpura. Archives of Disease in Childhood 1999, 80(4):380-3. 10.1136/adc.80.4.380, 1717896, 10086951.
13. Gibson KL, Amamoo MA, Primack WA. Corticosteroid therapy for Henoch Schönlein purpura. Pediatrics 121(4):870-1.
14. Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Schönlein nephritis. Pediatrics 2003, 111(4:Pt 1):t-9.
15. O'Neil KM. Progress in pediatric vasculitis. Current Opinion in Rheumatology 2009, 21(5):538-46. 10.1097/BOR.0b013e32832f13f1, 19568171.
16. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. Journal of Pediatrics 2008, 153(6):833-8. 10.1016/j.jpeds.2008.06.011, 2856847, 18672254.
17. Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. American Heart Journal 2011, 161(3):494-9. 10.1016/j.ahj.2010.12.003, 21392603.
18. Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatric Infectious Disease Journal 2010, 29(10):978-9. 10.1097/INF.0b013e3181e05564, 20431427.
19. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. Journal of Pediatrics 2011, 158(4):644-9. 10.1016/j.jpeds.2010.10.012, 21129756.
20. Antoniu SA. Treatment options for refractory Wegener's granulomatosis: a role for rituximab?. Current Opinion in Investigational Drugs 2007, 8(11):927-32.
21. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis. New England Journal of Medicine 2005, 352(4):351-61. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
22. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002, 206(5):496-501. 10.1078/0171-2985-00197, 12607724.
23. Botsios C, Sfriso P, Punzi L, Todesco S. Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra. Scandinavian Journal of Rheumatology 2007, 36(3):236-7. 10.1080/03009740600938647, 17657682.
24. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology 2009, 48(8):978-86. 10.1093/rheumatology/kep148, 19535611.
25. Huugen D, Tervaert JW, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clinical Journal of The American Society of Nephrology: CJASN 2006, 1(5):1100-7. 10.2215/CJN.02181205, 17699331.
26. Lamprecht P, Till A, Steinmann J, Aries PM, Gross WL. Current state of biologicals in the management of systemic vasculitis. Annals of the New York Academy of Sciences 2007, 1110:261-70. 10.1196/annals.1423.028, 17911441.
27. Lee RW, D'Cruz DP. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs 2008, 68(6):747-70. 10.2165/00003495-200868060-00003, 18416584.
28. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Medical Weekly 2011, 141:w13156.
29. Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, Bakkaloglu A, et al. The role of cytokines in Henoch Schönlein purpura. Scandinavian Journal of Rheumatology 1997, 26(6):456-60. 10.3109/03009749709065719, 9433407.
30. Flatau E, Kohn D, Schiller D, Lurie M, Levy E. Schönlein -Henoch syndrome in patients with familial Mediterranean fever. Arthritis & Rheumatism 1982, 25(1):42-7. 10.1002/art.1780250107, 21837725.
31. Caglar MK. Familial Mediterranean fever after recovery from Schönlein - Henoch syndrome. Arthritis & Rheumatism 1983, 26(12):1536.
32. Lange-Sperandio B, Mohring K, Gutzler F, Mehls O. Variable expression of vasculitis in siblings with familial Mediterranean fever. Pediatric Nephrology 2004, 19(5):539-43. 10.1007/s00467-004-1440-1, 15015067.
33. Soylu A, Kasap B, Turkmen M, Saylam GS, Kavukcu S. Febrile myalgia syndrome in familial Mediterranean fever. JCR: Journal of Clinical Rheumatology 2006, 12(2):93-6. 10.1097/01.rhu.0000208635.64537.10, 16601545.
34. Tekin M, Yalcinkaya F, Tumer N, Cakar N, Kocak H, Ozkaya N, et al. Familial Mediterranean fever--renal involvement by diseases other than amyloid. Nephrology Dialysis Transplantation 1999, 14(2):475-9.
35. Ozdogan H, Arisoy N, Kasapcapur O, Sever L, Caliskan S, Tuzuner N, et al. Vasculitis in familial Mediterranean fever. Journal of Rheumatology 1997, 24(2):323-7.
36. Saatci U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. European Journal of Pediatrics 1997, 156(8):619-23. 10.1007/s004310050677, 9266193.
37. Ozkaya O, Bek K, Alaca N, Ceyhan M, Acikgoz Y, Tasdemir HA. Cerebral vasculitis in a child with Henoch-Schönlein purpura and familial Mediterranean fever. Clinical Rheumatology 2007, 26(10):1729-32. 10.1007/s10067-006-0485-x, 17235658.
38. Balbir-Gurman A, Nahir AM, Braun-Moscovici Y. Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature. Clinical Rheumatology 2007, 26(7):1183-5. 10.1007/s10067-006-0323-1, 16721494.
39. Unal S, Gucer S, Kale G, Besbas N, Ozen S, Gumruk F. Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment. American Journal of Hematology 2008, 83(2):165-6. 10.1002/ajh.21052, 17712793.
40. Wickiser JE, Saulsbury FT. Henoch-Schönlein purpura in a child with hyperimmunoglobulinemia D and periodic fever syndrome. Pediatric Dermatology 2005, 22(2):138-41. 10.1111/j.1525-1470.2005.22210.x, 15804303.
41. Tarshish P, Bernstein J, Edelmann CM. Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatric Nephrology 2004, 19(1):51-6. 10.1007/s00467-003-1315-x, 14634864.
42. Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis. Pediatric Nephrology 1995, 9(1):6-10. 10.1007/BF00858954, 7742225.
43. Besbas N, Duzova A, Topaloglu R, Gok F, Ozaltin F, Ozen S, et al. Pulmonary haemorrhage in a 6-year-old boy with Henoch-Schönlein purpura. Clinical Rheumatology 2001, 20(4):293-6. 10.1007/PL00011205, 11529643.